ILE Isolagen

Isolagen Appoints Mark A. Kahil Vice President, Investor Relations EXTON, Pa., July 13 /PRNewswire-FirstCall/ -- Isolagen, Inc. (AMEX:ILE) is pleased to announce that Mark A. Kahil will join the Company as Vice President of Investor Relations beginning July 18th to develop and oversee the Company's external communications strategy within the investment community. Mr. Kahil brings to Isolagen an outstanding reputation based on more than 15 years of strategic investor relations experience, including broad investor relations roles in diverse industries ranging from small to large market capitalization with listings on NASDAQ, AMEX and NYSE. Most recently Mr. Kahil held the position of Sr. Director of Investor Relations for King Pharmaceuticals; prior assignments include Director of Investor Relations and Corporate Affairs for Sterling Chemicals and Manager of Investor Relations with two oil and gas companies. Mr. Kahil began his tenure in investor relations while serving as Vice President of an investor/public relations support firm for six years, where he advised more than 60 publicly traded companies on various investor relations strategies. From 1999-2000 Mr. Kahil served as President of the Houston Chapter of the National Investor Relations Institute after serving on the Board for several years prior. "We are excited to have Mr. Kahil join Isolagen. His proven ability to develop and implement a strategic investor relations program will be a valuable asset to the Company as we seek to increase our visibility within the financial community and assist the investment community in understanding our fundamental and financial capabilities," stated Frank DeLape, Chairman and acting CEO. Mr. Kahil received his MBA from Jones International University in May of 2003 and his BBA from Sam Houston State University in 1986. Additionally, Mr. Kahil is the recipient of The Leatherneck Award for Outstanding Achievement from the United States Marine Corps. Susan Ciallella, Executive Vice President, commented, "As we continue to take significant strides towards achieving our key business objectives, it is increasingly important to keep the investment community abreast of our progress. Mr. Kahil's experience and understanding of a well-rounded communications program will assist Isolagen in effectively communicating the significance of these achievements and in cultivating relationships with existing shareholders and potential investors." About Isolagen, Inc. Isolagen specializes in the development and commercialization of autologous cellular therapies for soft and hard tissue regeneration. The company's product candidates are based on its proprietary Isolagen Process. Based on the accumulated experience of the company through its retrospective study, clinical trials and treatment of patients in the United Kingdom, the company believes that the Isolagen Process utilizes the patient's own cells to create safe and effective therapies to treat the underlying cause of the patient's condition. Autologous cellular therapy is the process whereby a patient's own cells are extracted, allowed to multiply and then injected into the patient. Isolagen's product candidates are designed to be minimally invasive and non-surgical. Forward-looking statements in this release are made pursuant to the safe harbor provisions of the federal securities laws. Information contained in forward-looking statements is based on current expectations and is subject to change, and actual results may differ materially from the forward-looking statements. Isolagen, Inc. does not undertake to update any such forward-looking statements or to publicly announce developments or events relating to the matters described herein. For additional information, please visit: http://www.isolagen.com/ . DATASOURCE: Isolagen, Inc. CONTACT: Martin Schmieg, Chief Financial Officer of Isolagen, Inc., +1-484-875-3099; or investor relations, Kate McNeil or John Nesbett, +1-212-825-3210, both for Isolagen, Inc. Web site: http://www.isolagen.com/

Copyright